Compare Biogen Inc (BIIB) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Biogen Inc trades at $188.01 (market cap $28.34B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $107.29. The key difference: Biogen Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | LQD | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | — |
52-Week High | $216.63 | $112.91 |
52-Week Low | $122.68 | $106.96 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, trades at $106.96, down 0.47% on the day. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators suggest potential oversold conditions. Recent dividend payouts of $0.38-$0.42 per share highlight its income focus. Fixed income ETFs are gaining investor attention amid economic resilience and rate uncertainty, with bond inflows surging 60% year-over-year as of June 2026 (CNBC, 2026-06-25).
Outlook: LQD offers exposure to investment-grade corporate bonds with steady dividends, but faces headwinds from potential Fed rate hikes and inflation concerns. Risks include interest rate sensitivity and narrowing market breadth. Analyst comparisons favor LQD for lower drawdowns versus peers, but investors should weigh yield against Treasury alternatives. The ETF's performance hinges on macroeconomic policy shifts and corporate debt market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
